The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines
Open accessAbstract
Vaccines represent a major public health intervention against infectious diseases and potentially cancer. Surrogate markers of vaccine efficacy usually rely on neutralizing antibody titers afflicted by high interindividual variabilities. Automated multiplexed T cell assays currently allow to test the clinical relevance of T lymphocyte responses during vaccine rollout. We examined cellular and/or humoral immune responses in five independent cohorts of health care workers, young healthy individuals and patients with cancer (melanoma or lung cancer) receiving various immunizing formulations (non-replicating, viral/tumoral, mRNA/peptides/cellular/viral particles). Here we show that about 20% of vaccinees to non-replicating formulations fail to mount protective antibody and Th1/Tc1 responses while 9% receiving a live vaccine were hyperresponders. Vaccine outliers could at least in part be attributed to gut dysbiosis at baseline, evaluated by shotgun metagenomics-based machine learning or the TOPOSCORE. These findings highlight the requirement of diagnostic tools to identify intestinal dysbiosis, as well as microbiota-centered interventions to optimize the efficiency of mass vaccinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, CAR T-cells,237,238 hematopoietic stem cell transplantation,239 and vaccines244 are all affected by gut microbial composition.”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [244]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 22
- Carrier A. & Manghi P. & Alves Costa Silva C. & Lahmar I. et al. 6. Payton, T. et al. Immunogenicity, Safety and Tolerability of 3 Lots of 13-valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations in the United States. Pediatr. Infect. Dis. J. 32, 871 (2013).
- Finan, C., Ota, M. O. C., Marchant, A. & Newport, M. J. Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants. PLOS ONE 3, e3485 (2008).
- Grassly, N. C., Kang, G. & Kampmann, B. Biological challenges to effective vaccines in the developing world. Philos. Trans. R. Soc. B Biol. Sci. 370, 20140138 (2015).
- Ferreira, R. B. R., Antunes, L. C. M. & Finlay, B. B. Should the Human Microbiome Be Considered When Developing Vaccines? PLOS Pathog. 6, e1001190 (2010).
- Derosa, L. et al. Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome. Cell (in press).
- Bol, K. F. et al. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND- DC randomized phase III trial. Nat. Commun. 15, 1632 (2024).
- Tseng, C.-H. et al. Gastric microbiota and predicted gene functions are altered after subtotal gastrectomy in patients with gastric cancer. Sci. Rep. 6, 20701 (2016).
- Liu, N. et al. Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1. Cell Death Dis. 14, 170 (2023).
- Santos-Peral, A. et al. Basal T cell activation predicts yellow fever vaccine response independently of cytomegalovirus infection and sex-related immune variations. Cell Rep. Med. 6, 101946 (2025).
- Santos-Peral, A. et al. Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection. Nat. Commun. 15, 1696 (2024).
- Cheung, K.-S. et al. Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination. Vaccines 10, 1122 (2022).
- Hong, M. et al. A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines. Gut Microbes 15, 2233146 (2023).
- Jiao, J. et al. Characterization of the Intestinal Microbiome in Healthy Adults over Sars-Cov-2 Vaccination. Front. Biosci.-Landmark 27, 280 (2022).
- Carrier A. & Manghi P. & Alves Costa Silva C. & Lahmar I. et al. 57. Singer, J. et al. Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin -study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients. BMJ Open 12, e062747 (2022).
- Xu, J. et al. Boosting Vaccine-Elicited Respiratory Mucosal and Systemic COVID-19 Immunity in Mice With the Oral Lactobacillus plantarum. Front. Nutr. 8, 789242 (2021).
- Bonato, A. et al. 156P Microbiota-related multiomics to assess the clinical relevance of antibiotics (ATB) in immunotherapy (ICI). Ann. Oncol. 35, S277 (2024).
- Kim, C. G. et al. Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response. Cell Rep. Med. 4, 101251 (2023).
- Lamousé-Smith, E. S., Tzeng, A. & Starnbach, M. N. The Intestinal Flora Is Required to Support Antibody Responses to Systemic Immunization in Infant and Germ Free Mice. PLOS ONE 6, e27662 (2011).
- Bernard-Raichon, L. et al. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat. Commun. 13, 5926 (2022).
- Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep. Med. 2, 100204 (2021).
- Beghini, F. et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. eLife 10, e65088 (2021).
- Pasolli, E., Truong, D. T., Malik, F., Waldron, L. & Segata, N. Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights. PLOS Comput. Biol. 12, e1004977 (2016).
Cited by
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
Self-citation
Metadata
- Authors
- Zitvogel, L., Carrier, A., Manghi, P., Silva, C. A. C., Lahmar, I., Birebent, R., Suissa, D., Laheurte, C., Schreibelt, G., Lemant, L., FAHRNER, J.-E., de Sousa, E., Berthier, F., Villemonteix, J., Chevalier, M., Piccinno, G., Hocquet, D., Lebhar, I., Maeurer, M., Caillat-Zucman, S., Kroemer, G., Derosa, L., Launay, O., Golden, E., Bol, K., De Vries, I. J. M., Adotévi, O., Segata, N., Formenti, S., Kobold, S., Pieper, D., Vital, M., Santos-Peral, A., Zaucha, M., García-Bengoa, M., Thorn-Seshold, J., Stirling, H., Rothenfusser, S., Iebba, V., Almonte, A., Ajami, N., White, M., Sahasrabhojane, P., Hoballah, Y., Losh, J., DePinho, C., Dondossola, E., & Wargo, J.
- Affiliations
- Institut Gustave Roussy (FR)
- Fondazione Edmund Mach (IT)
- 2. Gustave Roussy Cancer Campus (GRCC), Clinicobiome, 94800 Villejuif Cedex, France.
- Inserm (FR)
- Radboud University Medical Center (NL)
- Champalimaud Foundation
- bioMérieux (France) (FR)
- Hôpital Saint-Louis (FR)
- University of Trento (IT)
- Université de Franche-Comté (FR)
- Champalimaud Foundation (PT)
- Assistance Publique Hôpitaux de Paris, Hôpital Saint-Louis
- Université Paris Cité (FR)
- Weill Cornell Medicine (US)
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center
- LMU Klinikum (DE)
- Centre for Infection Research
- Medizinische Hochschule Hannover (DE)
- Division of Clinical Pharmacology, LMU University Hospital, Munich, LMU Munich, 80336 Munich, Germany.
- Ludwig-Maximilians-Universität München (DE)
- University of Trieste (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Zitvogel, Laurence
- Carrier, Agathe
- Manghi, Paolo
- Silva, Carolina Alves Costa
- Birebent, Roxanne
- Laheurte, Caroline
- Schreibelt, Gerty
- FAHRNER, Jean-Eudes
- de Sousa, Eric
- Berthier, Franck
- Villemonteix, Juliette
- Chevalier, Mathieu
- Piccinno, Gianmarco
- Hocquet, Didier
- Maeurer, Markus
- Caillat-Zucman, Sophie
- Kroemer, Guido
- Derosa, Lisa
- Launay, Odile
- Bol, Kalijn
- De Vries, I. Jolanda M.
- Adotévi, Olivier
- Segata, Nicola
- Formenti, Silvia
- Kobold, Sebastian
- Pieper, Dietmar
- Vital, Marius
- Zaucha, Magdalena
- García-Bengoa, María
- Thorn-Seshold, Julia
- Rothenfusser, Simon
- Iebba, Valerio
- Almonte, Andrew
- Ajami, Nadim
- White, Michael
- Losh, Jillian
- Dondossola, Eleonora
- Wargo, Jennifer
- Venue
- Research Square
- Published
- 2025-10-28
- PMC
- PMC12636744
- OpenAlex
- W4415623004
- Cited by
- 1
- References
- 0
- Citations by year
- 2026: 1
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Locations
- Research Square (acceptedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- Melanoma Research Alliance (409510)
- Regeneron Pharmaceuticals
- Celldex Therapeutics
- Les Laboratories Pierre Fabre
- European Commission (825410, 101045015, HORIZON2020, 756017, 955575, 101137459)
- Deutsche Forschungsgemeinschaft (SFB-TRR 338/1, KO5055-2-1, 369799452, 391217598, TRR 237, KO5055/3-1, SFB-TRR 338)
- Agence Nationale de la Recherche (ANR-17-CE15-0031, ANR-17)
- Institut National de la Santé et de la Recherche Médicale
- ZonMw
- Bayerische Forschungsstiftung
- Ludwig-Maximilians-Universität München
- Deutsche Krebshilfe
- Assistance publique-Hôpitaux de Paris
- Zorginstituut Nederland
- Servier
- Hector Stiftung
- Institut Servier
- National Institutes of Health (CA- 016672, 1u01ca230551-01a1, 1U01CA230551)
- Genentech
- Weill Cornell Medical College
- University of Texas MD Anderson Cancer Center ((CA016672), P30-CA-016672)
- Stand Up To Cancer
- HORIZON EUROPE Framework Programme (101137459)
- Elitenetzwerk Bayern (409510)
- Helmholtz Zentrum München
- National Cancer Institute (CA 016672, 1U01CA230551, P30CA016672)
- HORIZON EUROPE European Research Council (101100460, 101124203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gut microbiota, vaccine immunogenicity, cancer vaccines, viral vaccines, gut dysbiosis, humoral immune response, melanoma, lung cancer, healthcare workers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines. https://app.cochat.ai/papers/10.21203/rs.3.rs-4294379/v1
- The paper
- Zitvogel, L., Carrier, A., Manghi, P., Silva, C. A. C., Lahmar, I., Birebent, R., Suissa, D., Laheurte, C., Schreibelt, G., Lemant, L., FAHRNER, J.-E., de Sousa, E., Berthier, F., Villemonteix, J., Chevalier, M., Piccinno, G., Hocquet, D., Lebhar, I., Maeurer, M., . . . Wargo, J. (2025). Gut microbiota: a new factor modulating the immunizing potential of viral and cancer vaccines. Research Square. https://doi.org/10.21203/rs.3.rs-4294379/v1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.